title: The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platform.
abstract: The development of resources for clinical interpretation of cancer-associated genetic alterations has significantly lagged behind the technical developments enabling their detection in a time- and cost-efficient manner. The lack of scientific and informatics decision support for oncologists can lead to no action being taken or suboptimal therapeutic choices being made, which could affect the clinical outcome of a patient as well as convoluting research findings from clinical trials. In this article, we describe the precision oncology decision support (PODS) platform developed within The Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy (IPCT) at MD Anderson Cancer Center; the platform aims to bridge the gap between molecular alteration detection and identification of appropriate treatments.
authors.affiliation: Sheikh Khalifa Al Nahyan Ben Zayed Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
authors.forename: Amber
authors.initials: A
authors.lastname: Johnson
authors.affiliation: Sheikh Khalifa Al Nahyan Ben Zayed Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
authors.forename: Jia
authors.initials: J
authors.lastname: Zeng
authors.affiliation: Sheikh Khalifa Al Nahyan Ben Zayed Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
authors.forename: Ann M
authors.initials: AM
authors.lastname: Bailey
authors.affiliation: Sheikh Khalifa Al Nahyan Ben Zayed Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
authors.forename: Vijaykumar
authors.initials: V
authors.lastname: Holla
authors.affiliation: Sheikh Khalifa Al Nahyan Ben Zayed Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
authors.forename: Beate
authors.initials: B
authors.lastname: Litzenburger
authors.affiliation: Sheikh Khalifa Al Nahyan Ben Zayed Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
authors.forename: Humberto
authors.initials: H
authors.lastname: Lara-Guerra
authors.affiliation: Sheikh Khalifa Al Nahyan Ben Zayed Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
authors.forename: Gordon B
authors.initials: GB
authors.lastname: Mills
authors.affiliation: Sheikh Khalifa Al Nahyan Ben Zayed Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
authors.forename: John
authors.initials: J
authors.lastname: Mendelsohn
authors.affiliation: Sheikh Khalifa Al Nahyan Ben Zayed Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
authors.forename: Kenna R
authors.initials: KR
authors.lastname: Shaw
authors.affiliation: Sheikh Khalifa Al Nahyan Ben Zayed Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: fmeric@mdanderson.org.
authors.forename: Funda
authors.initials: F
authors.lastname: Meric-Bernstam
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D008495:Medical Oncology / Q000379:methods; D009369:Neoplasms / Q000188:drug therapy*; D057285:Precision Medicine / Q000379:methods; D012106:Research
chemical_list: D000970:Antineoplastic Agents